# of Displayed Technologies: 20 / 38

Applied Category Filter (Click To Remove): Life Sciences


Categories

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: Flammang, Ann Marie

Method for diagnosis and prognosis of Alzheimer's disease
TS-050046 — Methods using miRNAs for early Alzheimer’s Disease diagnoses and altered expression of key autophagy related proteins
The Need Alzheimer’s Disease (AD) is the most common cause of age-related dementia leading to severe and irreversible neurodegeneration and cognitive decline. Currently, AD has no cure or effective preventive approaches. Using current diagnostic techniques, AD cannot be clinically diagnosed b…
  • College: College of Medicine (COM)
  • Inventors: Amer, Amal
  • Licensing Officer: Flammang, Ann Marie

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Flammang, Ann Marie

mRNA sequence engineering and uses thereof
TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Flammang, Ann Marie

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Flammang, Ann Marie

Improved Dressing Design for Insertion Sheaths with Side Ports
TS-044969 — Dressing designed and tailored exclusively for insertion sheaths with side ports, used frequently for pulmonary artery catheters (PACs or Swan-Ganz catheters) among other intravascular devices in the hospital.
The Need Central-line associated blood stream infections (CLABSIs) are a life-threatening and extremely costly problem in hospitals around the world. When patients in the hospital have indwelling catheters such as pulmonary artery catheters, they are at an increased risk of developing such infectio…
  • College: OSU Wexner Medical Center
  • Inventors: Warren, Samantha; Thomas, Jordan
  • Licensing Officer: Flammang, Ann Marie

Biomimetic vitreous substitute with ocular drug delivery
TS-044490 — Methods and compositions for an antioxidant releasing hydrogel vitreous substitute
The vitreous humor is a fragile, transparent tissue between the lens and the retina of the eye that maintains the shape of the eye, acts as a shock absorber, and enables nutrient diffusion to ocular tissues. The vitreous also plays a key role in oxygen homeostasis. Over time, the vitreous degrades…
  • College: College of Engineering (COE)
  • Inventors: Swindle-Reilly, Katelyn; Reilly, Matthew; Tram, Nguyen "Archie"
  • Licensing Officer: Flammang, Ann Marie

Composition and method of lipid nanoparticles carrying oligonucleotides
TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment
Lung cancer is the leading cause of cancer related deaths in the US with approximately 150,000 deaths in 2017. Currently, mildly ineffective chemotherapeutics ripe with adverse side effects are the standard treatment. Antisense oligonucleotides (ASOs) are able to selectively modulate expression of…
  • College: College of Pharmacy
  • Inventors: Lee, Robert; Cheng, Xinwei "Evan"
  • Licensing Officer: Flammang, Ann Marie

A Bi-layered Capsule for Sustainable Delivery of Protein Therapeutics
TS-042858 — A biodegradable drug delivery system for the treatment of disease, especially ophthalmic diseases including age-related macular degeneration (AMD). The device will be injected and can control drug release for at least 6 months following the initial injection.
Retinal diseases can be extremely difficult to monitor once procedures have been initiated. AMD is the fourth most common causes of blindness and requires monthly injections to manage the effects of the disease and prevent permanent blindness. However, receiving recurrent injections can potentiall…
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Coutinho da Silva, Marco; Lannutti, John; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Engineered Cells for Treatment of Animal Metabolic Disorders
TS-041976 — The implantation of engineered thermogenic cells for treating metabolic disease and obesity in animals.
Obesity remains one of the main underlying causes for many malignancies in domestic animals such as cats, dogs, and horses. From a veterinary perspective, obesity dramatically increases the risk of cancer, one of the leading causes of death in domesticated animals. Other diseases correlated with o…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana
  • Licensing Officer: Flammang, Ann Marie

Engineered Cells for Treatment of Animal Metabolic Disorders
TS-041976 — The implantation of engineered thermogenic cells for treating metabolic disease and obesity in animals.
Obesity remains one of the main underlying causes for many malignancies in domestic animals such as cats, dogs, and horses. From a veterinary perspective, obesity dramatically increases the risk of cancer, one of the leading causes of death in domesticated animals. Other diseases correlated with o…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana
  • Licensing Officer: Flammang, Ann Marie

Junctional Tourniquet for Groin and Axillary Regions
TS-041808 — A tourniquet with a ratcheting lock to keep pressure on wounds in the groin and axillary regions. Hemostasis can be achieved while the patient is still in the field.
Patients with blood loss in the field need to be treated immediately to prevent ongoing blood loss, shock, and death; bleeding from extremity and junctional wounds is the leading cause of potentially preventable death from penetrating injuries. Direct manual pressure is effective for the initial c…
  • College: OSU Wexner Medical Center
  • Inventors: McElroy, James; Graham, Nadi; Nocera, Tanya
  • Licensing Officer: Flammang, Ann Marie

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Novel Foam Collector for Bioreactors
TS-039273 — A foam collector to be used with bioreactors that would target and remove secondary metabolites produced and held within foam that is a product of the chemical reactions conducted.
Certain chemical reactions conducted in bioreactors, like aerobic fermentation, can produce a persistent foam that fills the headspace of the reactor vessels in which the reaction is taking place. This foam can be removed by introducing surface agents, but this is extremely undesirable as these ag…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Yousef, Ahmed; Campbell, Emily; Kasler, David
  • Licensing Officer: Flammang, Ann Marie

Productivity model for Advanced Practice Providers
TS-038991 — A new, well-rounded system of measuring APP productivity
Physician assistants (PAs) and nurse practitioners (NPs) are referred to as advanced practice providers (APPs). They are certified health care professionals who provide care and treatment to patients in collaboration with physicians. Although they are an integral part of many clinics and hospitals…
  • College: OSU Wexner Medical Center
  • Inventors: Rosselet, Robin; Cackler, Scott
  • Licensing Officer: Flammang, Ann Marie

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Sustained Release Microparticles for the Treatment of Ocular Diseases
TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals 65 and older and is the third leading cause of blindness worldwide. Wet AMD is characterized by abnormal growth of leaky blood vessels leading to damage to the macula of the retina resulting in vision loss and …
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Methods for generation of TF-targeting chimeric antigen receptors (CARs)-natural killer cells and T cells
TS-038262 — A therapeutic application of neovascular-targeting chimeric antigen receptor (CAR) T cells and NK cells for treating diseases associated with pathological angiogenesis, in which TF is abarrently expressed, such as solid tumors, leukemia, lymphoma, age-related macular degeneration (AMD), endometriosis, and rheumatoid arthritis.
Nearly 2,000,000 new cancer cases are expected to be diagnosed each year in the United States. Available treatment options include surgery, radiation therapy, chemotherapy, and immunotherapy. Recently, cell-based immunotherapy utilizing specific chimeric antigen receptor (CAR) expressing immune ce…
  • College: College of Medicine (COM)
  • Inventors: Hu, Zhiwei
  • Licensing Officer: Flammang, Ann Marie

Amino Esters and Uses Thereof
TS-037840 — Amino esters nanomaterials for gene therapy and drug delivery.
The Need The efficient delivery of mRNA is a key challenge for the application of mRNA therapeutics. Despite promising data from ongoing clinical trials for the treatment of cancer vaccines, the clinical use of mRNA requires the discovery and development of safer and more effective delivery systems…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Luo, Xiao; Zhang, Xinfu
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

Loading icon